Elizabeth K Seng1,2,3, Alexandra B Singer4,5, Christopher Metts6, Amy S Grinberg4, Zarine S Patel1, Maya Marzouk1, Lauren Rosenberg1, Melissa Day7, Mia T Minen8, Richard B Lipton2, Dawn C Buse2. 1. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA. 2. Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA. 3. Montefiore Headache Center, Montefiore Medical Center, Bronx, NY, USA. 4. Psychology Service, VA Connecticut Healthcare System, West Haven, CT, USA. 5. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 6. Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA. 7. School of Psychology, University of Queensland, Brisbane, QLD, Australia. 8. Department of Neurology, New York University Langone Health, New York, NY, USA.
Abstract
OBJECTIVE: The current Phase 2b study aimed to evaluate the efficacy of mindfulness-based cognitive therapy for migraine (MBCT-M) to reduce migraine-related disability in people with migraine. BACKGROUND: Mindfulness-based interventions represent a promising avenue to investigate effects in people with migraine. MBCT teaches mindfulness meditation and cognitive-behavioral skills and directly applies these skills to address disease-related cognitions. METHODS:Participants with migraine (6-30 headache days/month) were recruited from neurology office referrals and local and online advertisements in the broader New York City area. During the 30-day baseline period, all participants completed a daily headache diary. Participants who met inclusion and exclusion criteria were randomized in a parallel design, stratified by chronic migraine status, to receive either 8 weekly individual MBCT-M sessions or 8 weeks of waitlist/treatment as usual (WL/TAU). All participants completed surveys including primary outcome evaluations at Months 0, 1, 2, and 4. All participants completed a headache diary during the 30-day posttreatment evaluation period. Primary outcomes were the change from Month 0 to Month 4 in the headache disability inventory (HDI) and the Migraine Disability Assessment (MIDAS) (total score ≥ 21 indicating severe disability); secondary outcomes (headache days/30 days, average headache attack pain intensity, and attack-level migraine-related disability [Migraine Disability Index (MIDI)]) were derived from the daily headache diary. RESULTS:Sixty participants were randomized to receive MBCT-M (n = 31) or WL/TAU (n = 29). Participants (M age = 40.1, SD = 11.7) were predominantly White (n = 49/60; 81.7%) and Non-Hispanic (N = 50/60; 83.3%) women (n = 55/60; 91.7%) with a graduate degree (n = 35/60; 55.0%) who were working full-time (n = 38/60; 63.3%). At baseline, the average HDI score (51.4, SD = 19.0) indicated a moderate level of disability and the majority of participants (50/60, 83.3%) fell in the "Severe Disability" range in the MIDAS. Participants recorded an average of 16.0 (SD = 5.9) headache days/30 days, with an average headache attack pain intensity of 1.7 on a 4-point scale (SD = 0.3), indicating moderate intensity. Average levels of daily disability reported on the MIDI were 3.1/10 (SD = 1.8). For the HDI, mean scores decreased more from Month 0 to Month 4 in the MBCT-M group (-14.3) than the waitlist/treatment as an usual group (-0.2; P < .001). For the MIDAS, the group*month interaction was not significant when accounting for the divided alpha, P = .027; across all participants in both groups, the estimated proportion of participants falling in the "Severe Disability" category fell significantly from 88.3% at Month 0 to 66.7% at Month 4, P < .001. For diary-reported headache days/30 days an average headache attack pain intensity, neither the group*month interaction (Ps = .773 and .888, respectively) nor the time effect (Ps = .059 and .428, respectively) was significant. Mean MIDI scores decreased in the MBCT-M group (-0.6/10), whereas they increased in the waitlist/treatment as an usual group (+0.3/10), P = .007. CONCLUSIONS: MBCT-M demonstrated efficacy to reduce headache-related disability and attack-level migraine-related disability. MBCT-M is a promising emerging treatment for addressing migraine-related disability.
RCT Entities:
OBJECTIVE: The current Phase 2b study aimed to evaluate the efficacy of mindfulness-based cognitive therapy for migraine (MBCT-M) to reduce migraine-related disability in people with migraine. BACKGROUND: Mindfulness-based interventions represent a promising avenue to investigate effects in people with migraine. MBCT teaches mindfulness meditation and cognitive-behavioral skills and directly applies these skills to address disease-related cognitions. METHODS:Participants with migraine (6-30 headache days/month) were recruited from neurology office referrals and local and online advertisements in the broader New York City area. During the 30-day baseline period, all participants completed a daily headache diary. Participants who met inclusion and exclusion criteria were randomized in a parallel design, stratified by chronic migraine status, to receive either 8 weekly individual MBCT-M sessions or 8 weeks of waitlist/treatment as usual (WL/TAU). All participants completed surveys including primary outcome evaluations at Months 0, 1, 2, and 4. All participants completed a headache diary during the 30-day posttreatment evaluation period. Primary outcomes were the change from Month 0 to Month 4 in the headache disability inventory (HDI) and the Migraine Disability Assessment (MIDAS) (total score ≥ 21 indicating severe disability); secondary outcomes (headache days/30 days, average headache attack pain intensity, and attack-level migraine-related disability [Migraine Disability Index (MIDI)]) were derived from the daily headache diary. RESULTS: Sixty participants were randomized to receive MBCT-M (n = 31) or WL/TAU (n = 29). Participants (M age = 40.1, SD = 11.7) were predominantly White (n = 49/60; 81.7%) and Non-Hispanic (N = 50/60; 83.3%) women (n = 55/60; 91.7%) with a graduate degree (n = 35/60; 55.0%) who were working full-time (n = 38/60; 63.3%). At baseline, the average HDI score (51.4, SD = 19.0) indicated a moderate level of disability and the majority of participants (50/60, 83.3%) fell in the "Severe Disability" range in the MIDAS. Participants recorded an average of 16.0 (SD = 5.9) headache days/30 days, with an average headache attack pain intensity of 1.7 on a 4-point scale (SD = 0.3), indicating moderate intensity. Average levels of daily disability reported on the MIDI were 3.1/10 (SD = 1.8). For the HDI, mean scores decreased more from Month 0 to Month 4 in the MBCT-M group (-14.3) than the waitlist/treatment as an usual group (-0.2; P < .001). For the MIDAS, the group*month interaction was not significant when accounting for the divided alpha, P = .027; across all participants in both groups, the estimated proportion of participants falling in the "Severe Disability" category fell significantly from 88.3% at Month 0 to 66.7% at Month 4, P < .001. For diary-reported headache days/30 days an average headache attack pain intensity, neither the group*month interaction (Ps = .773 and .888, respectively) nor the time effect (Ps = .059 and .428, respectively) was significant. Mean MIDI scores decreased in the MBCT-M group (-0.6/10), whereas they increased in the waitlist/treatment as an usual group (+0.3/10), P = .007. CONCLUSIONS: MBCT-M demonstrated efficacy to reduce headache-related disability and attack-level migraine-related disability. MBCT-M is a promising emerging treatment for addressing migraine-related disability.
Authors: Rachel L Tomko; Michael E Saladin; Nathaniel L Baker; Erin A McClure; Matthew J Carpenter; Viswanathan R Ramakrishnan; Bryan W Heckman; Jennifer M Wray; Katherine T Foster; Stephen T Tiffany; Christopher L Metts; Kevin M Gray Journal: Nicotine Tob Res Date: 2020-01-27 Impact factor: 4.244
Authors: Ingeborg Farver-Vestergaard; Maja O'Connor; Nina C Smith; Anders Løkke; Elisabeth Bendstrup; Robert Zachariae Journal: J Telemed Telecare Date: 2018-06-25 Impact factor: 6.184
Authors: Rebecca Erwin Wells; Elizabeth K Seng; Robert R Edwards; David E Victorson; Charles R Pierce; Lauren Rosenberg; Vitaly Napadow; Zev Schuman-Olivier Journal: Expert Rev Neurother Date: 2020-02-12 Impact factor: 4.618
Authors: Elizabeth K Seng; Alexandra B Conway; Amy S Grinberg; Zarine S Patel; Maya Marzouk; Lauren Rosenberg; Christopher Metts; Melissa A Day; Mia T Minen; Dawn C Buse; Richard B Lipton Journal: Neurol Clin Pract Date: 2021-06
Authors: Abby L Cheng; Brian K Brady; Ethan C Bradley; Ryan P Calfee; Lisa M Klesges; Graham A Colditz; Heidi Prather Journal: PM R Date: 2021-05-03 Impact factor: 2.298
Authors: Mia T Minen; Benjamin W Friedman; Samrachana Adhikari; Sarah Corner; Scott W Powers; Elizabeth K Seng; Corita Grudzen; Richard B Lipton Journal: Gen Hosp Psychiatry Date: 2021-01-08 Impact factor: 3.238
Authors: Mia T Minen; Samrachana Adhikari; Jane Padikkala; Sumaiya Tasneem; Ashley Bagheri; Eric Goldberg; Scott Powers; Richard B Lipton Journal: Headache Date: 2020-11-16 Impact factor: 5.887
Authors: Prisca R Bauer; Else A Tolner; Mark R Keezer; Michel D Ferrari; Josemir W Sander Journal: Nat Rev Neurol Date: 2021-07-26 Impact factor: 42.937